The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia.
Identifieur interne : 000086 ( Main/Exploration ); précédent : 000085; suivant : 000087The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia.
Auteurs : Gerard Espinosa [Espagne] ; Sergio Prieto-González [Espagne] ; Mireia Llevadot [Espagne] ; Javier Marco-Hernández [Espagne] ; Antonio Martínez-Artu A [Espagne] ; Albert Pérez-Isidro [Espagne] ; Elia Rifé [Espagne] ; Ricard Cervera [Espagne]Source :
- Clinical rheumatology [ 1434-9949 ] ; 2021.
Descripteurs français
- KwdFr :
- MESH :
- épidémiologie : Espagne, Lupus érythémateux disséminé.
- Humains, Études transversales.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- MESH :
- geographic , epidemiology : Spain.
- complications : Lupus Erythematosus, Systemic.
- epidemiology : Lupus Erythematosus, Systemic.
- COVID-19, Cross-Sectional Studies, Humans, SARS-CoV-2.
Abstract
OBJECTIVE
To evaluate the incidence and characteristics of SARS-CoV-2 infection among patients with systemic lupus erythematosus (SLE) and to compare it to that described in the general population.
METHODS
For 5 weeks, we carried out a cross-sectional study consisting of telephone interviews of SLE patients. We collected epidemiological data, symptoms suggesting COVID-19, results of nasopharyngeal swabs, and ongoing treatments. In those patients who required hospital admission, clinical, radiological, and laboratory features, and outcome were investigated.
RESULTS
Four hundred patients with SLE completed the survey. Overall, 4 (1.00%, 95%CI 0.02-1.98) patients were classified as confirmed cases of COVID-19 and 26 (6.51%, 95%CI 4.08-8.94) as possible clinical cases. The incidence of confirmed cases in our series was similar to that of the Catalan population (1.00% versus 0.63%; p = 0.456), whereas the incidence of possible cases was higher in our series (6.51% versus 1.29%; p < 0.005). The only difference between SLE patients with confirmed and possible COVID-19 and those without was the percentage of patients who have had contact with a confirmed or possible case of COVID-19 (26.7% versus 9.2%; p = 0.003) CONCLUSIONS: The incidence of COVID-19 in SLE patients with inactive disease is low and, in our series, all cases with confirmed infection recovered. Key Points • In a cohort of SLE patients with stable and clinical inactive disease, the incidence of COVID-19 is low. • All SLE patients with confirmed SARS-CoV-2 infection recovered.
DOI: 10.1007/s10067-021-05675-x
PubMed: 33677725
PubMed Central: PMC7936868
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia.</title><author><name sortKey="Espinosa, Gerard" sort="Espinosa, Gerard" uniqKey="Espinosa G" first="Gerard" last="Espinosa">Gerard Espinosa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona, Spain. gespino@clinic.cat.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Prieto Gonzalez, Sergio" sort="Prieto Gonzalez, Sergio" uniqKey="Prieto Gonzalez S" first="Sergio" last="Prieto-González">Sergio Prieto-González</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Llevadot, Mireia" sort="Llevadot, Mireia" uniqKey="Llevadot M" first="Mireia" last="Llevadot">Mireia Llevadot</name><affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Marco Hernandez, Javier" sort="Marco Hernandez, Javier" uniqKey="Marco Hernandez J" first="Javier" last="Marco-Hernández">Javier Marco-Hernández</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Martinez Artu A, Antonio" sort="Martinez Artu A, Antonio" uniqKey="Martinez Artu A A" first="Antonio" last="Martínez-Artu A">Antonio Martínez-Artu A</name><affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Perez Isidro, Albert" sort="Perez Isidro, Albert" uniqKey="Perez Isidro A" first="Albert" last="Pérez-Isidro">Albert Pérez-Isidro</name><affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, Hospital Clínic, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Immunology, Hospital Clínic, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Rife, Elia" sort="Rife, Elia" uniqKey="Rife E" first="Elia" last="Rifé">Elia Rifé</name><affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Cervera, Ricard" sort="Cervera, Ricard" uniqKey="Cervera R" first="Ricard" last="Cervera">Ricard Cervera</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33677725</idno><idno type="pmid">33677725</idno><idno type="doi">10.1007/s10067-021-05675-x</idno><idno type="pmc">PMC7936868</idno><idno type="wicri:Area/Main/Corpus">000268</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000268</idno><idno type="wicri:Area/Main/Curation">000268</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000268</idno><idno type="wicri:Area/Main/Exploration">000268</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia.</title><author><name sortKey="Espinosa, Gerard" sort="Espinosa, Gerard" uniqKey="Espinosa G" first="Gerard" last="Espinosa">Gerard Espinosa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona, Spain. gespino@clinic.cat.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Prieto Gonzalez, Sergio" sort="Prieto Gonzalez, Sergio" uniqKey="Prieto Gonzalez S" first="Sergio" last="Prieto-González">Sergio Prieto-González</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Llevadot, Mireia" sort="Llevadot, Mireia" uniqKey="Llevadot M" first="Mireia" last="Llevadot">Mireia Llevadot</name><affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Marco Hernandez, Javier" sort="Marco Hernandez, Javier" uniqKey="Marco Hernandez J" first="Javier" last="Marco-Hernández">Javier Marco-Hernández</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Martinez Artu A, Antonio" sort="Martinez Artu A, Antonio" uniqKey="Martinez Artu A A" first="Antonio" last="Martínez-Artu A">Antonio Martínez-Artu A</name><affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Perez Isidro, Albert" sort="Perez Isidro, Albert" uniqKey="Perez Isidro A" first="Albert" last="Pérez-Isidro">Albert Pérez-Isidro</name><affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, Hospital Clínic, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Immunology, Hospital Clínic, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Rife, Elia" sort="Rife, Elia" uniqKey="Rife E" first="Elia" last="Rifé">Elia Rifé</name><affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Cervera, Ricard" sort="Cervera, Ricard" uniqKey="Cervera R" first="Ricard" last="Cervera">Ricard Cervera</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><series><title level="j">Clinical rheumatology</title><idno type="eISSN">1434-9949</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (MeSH)</term><term>Cross-Sectional Studies (MeSH)</term><term>Humans (MeSH)</term><term>Lupus Erythematosus, Systemic (complications)</term><term>Lupus Erythematosus, Systemic (epidemiology)</term><term>SARS-CoV-2 (MeSH)</term><term>Spain (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Espagne (épidémiologie)</term><term>Humains (MeSH)</term><term>Lupus érythémateux disséminé (complications)</term><term>Lupus érythémateux disséminé (épidémiologie)</term><term>Études transversales (MeSH)</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lupus Erythematosus, Systemic</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Lupus Erythematosus, Systemic</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Lupus érythémateux disséminé</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Cross-Sectional Studies</term><term>Humans</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Études transversales</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To evaluate the incidence and characteristics of SARS-CoV-2 infection among patients with systemic lupus erythematosus (SLE) and to compare it to that described in the general population.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>For 5 weeks, we carried out a cross-sectional study consisting of telephone interviews of SLE patients. We collected epidemiological data, symptoms suggesting COVID-19, results of nasopharyngeal swabs, and ongoing treatments. In those patients who required hospital admission, clinical, radiological, and laboratory features, and outcome were investigated.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Four hundred patients with SLE completed the survey. Overall, 4 (1.00%, 95%CI 0.02-1.98) patients were classified as confirmed cases of COVID-19 and 26 (6.51%, 95%CI 4.08-8.94) as possible clinical cases. The incidence of confirmed cases in our series was similar to that of the Catalan population (1.00% versus 0.63%; p = 0.456), whereas the incidence of possible cases was higher in our series (6.51% versus 1.29%; p < 0.005). The only difference between SLE patients with confirmed and possible COVID-19 and those without was the percentage of patients who have had contact with a confirmed or possible case of COVID-19 (26.7% versus 9.2%; p = 0.003) CONCLUSIONS: The incidence of COVID-19 in SLE patients with inactive disease is low and, in our series, all cases with confirmed infection recovered. Key Points • In a cohort of SLE patients with stable and clinical inactive disease, the incidence of COVID-19 is low. • All SLE patients with confirmed SARS-CoV-2 infection recovered.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33677725</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia.</ArticleTitle><Pagination><MedlinePgn>2057-2063</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-021-05675-x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the incidence and characteristics of SARS-CoV-2 infection among patients with systemic lupus erythematosus (SLE) and to compare it to that described in the general population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">For 5 weeks, we carried out a cross-sectional study consisting of telephone interviews of SLE patients. We collected epidemiological data, symptoms suggesting COVID-19, results of nasopharyngeal swabs, and ongoing treatments. In those patients who required hospital admission, clinical, radiological, and laboratory features, and outcome were investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four hundred patients with SLE completed the survey. Overall, 4 (1.00%, 95%CI 0.02-1.98) patients were classified as confirmed cases of COVID-19 and 26 (6.51%, 95%CI 4.08-8.94) as possible clinical cases. The incidence of confirmed cases in our series was similar to that of the Catalan population (1.00% versus 0.63%; p = 0.456), whereas the incidence of possible cases was higher in our series (6.51% versus 1.29%; p < 0.005). The only difference between SLE patients with confirmed and possible COVID-19 and those without was the percentage of patients who have had contact with a confirmed or possible case of COVID-19 (26.7% versus 9.2%; p = 0.003) CONCLUSIONS: The incidence of COVID-19 in SLE patients with inactive disease is low and, in our series, all cases with confirmed infection recovered. Key Points • In a cohort of SLE patients with stable and clinical inactive disease, the incidence of COVID-19 is low. • All SLE patients with confirmed SARS-CoV-2 infection recovered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Espinosa</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1336-0163</Identifier><AffiliationInfo><Affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona, Spain. gespino@clinic.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Prieto-González</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7242-5265</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llevadot</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marco-Hernández</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Artuña</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-Isidro</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, Hospital Clínic, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rifé</LastName><ForeName>Elia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervera</LastName><ForeName>Ricard</ForeName><Initials>R</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6085-492X</Identifier><AffiliationInfo><Affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel, 08036, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Outbreak</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>02</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>7</Day><Hour>20</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33677725</ArticleId><ArticleId IdType="doi">10.1007/s10067-021-05675-x</ArticleId><ArticleId IdType="pii">10.1007/s10067-021-05675-x</ArticleId><ArticleId IdType="pmc">PMC7936868</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>European Centre for Disease Prevention and Control https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases . Accessed 13th Feb 2021</Citation></Reference><Reference><Citation>Pires da Rosa G, Fontecha Ortega M, Teixeira A, Espinosa G, Cervera R (2019) Causes and factors related to hospitalizations in patients with systemic lupus erythematosus: analysis of a 20-year period (1995–2015) from a single referral centre in Catalonia. Lupus 28:1158–1166. https://doi.org/10.1177/0961203319861685</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319861685</ArticleId><ArticleId IdType="pubmed">31299879</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Dai SM, Tong Q (2020) COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 75:1667–1670. https://doi.org/10.1093/jac/dkaa114</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa114</ArticleId><ArticleId IdType="pubmed">32196083</ArticleId></ArticleIdList></Reference><Reference><Citation>Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, Hensley SE, Gill S, Vogl DT, Maillard I, Babushok DV, Huang AC, Nasta SD, Walsh JC, Wiletyo EP, Gimotty PA, Milone MC, Amaravadi RK, Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators (2020) Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med 181:195–202. https://doi.org/10.1001/jamainternmed.2020.6319</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.6319</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware DR, Pullen MF, Bangdiwala AS (2020) A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. N Engl J Med. 383:517–525. https://doi.org/10.1056/NEJMoa2016638</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2016638</ArticleId><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>Data from: COVID-19 Global Rheumatology Alliance Global Registry https://rheum-covid.org/updates/combined-data.html . Accessed 13th Feb 2021</Citation></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR (2019) 2019 European League against rheumatism/American College of Rheumatology Classification Criteria for systemic lupus erythematosus. Arthritis Rheum 71:1400–1412. https://doi.org/10.1002/art.40930</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz P et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369. https://doi.org/10.1002/art.1780390303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control. Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020. Available from: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition . Accessed 1st June 2020</Citation></Reference><Reference><Citation>Data from: Conselleria de Salut, Govern de la Generalitat de Catalunya https://govern.cat/govern/docs/2020/04/25/22/07/b42d0b96-3891-4d83-a868-3c3dc36ae88b.pdf . Accessed 13th April 2020</Citation></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79:859–866. https://doi.org/10.1136/annrheumdis-2020-217871</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrejón I, Alvaro-Gracia JM, Fernández Fernández D, Mera-Varela A, Manrique-Arija S, Mena Vázquez N, Fernandez-Nebro A, RIER Investigators Group, RIER investigators group (2020) Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 79:1544–1154. https://doi.org/10.1136/annrheumdis-2020-218296</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218296</ArticleId><ArticleId IdType="pubmed">32796045</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama S, Hamdeh S, Micic D, Sakuraba A (2020) Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis Oct 13:annrheumdis-2020-218946. https://doi.org/10.1136/annrheumdis-2020-218946</Citation></Reference><Reference><Citation>Ramirez GA, Moroni L, Della-Torre E, Gerosa M, Beretta L, Bozzolo EP, Dagna L (2020) Systemic lupus erythematosus and COVID-19: what we know so far. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218601</Citation></Reference><Reference><Citation>Emmi G, Bettiol A, Mattioli I, Silvestri S, Di Scala G, Urban ML, Vaglio A, Prisco D (2020) SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev 19:102575. https://doi.org/10.1016/j.autrev.2020.102575</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102575</ArticleId><ArticleId IdType="pubmed">32376395</ArticleId><ArticleId IdType="pmcid">7200134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L (2020) COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 79:1382–1383. https://doi.org/10.1136/annrheumdis-2020-217717</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217717</ArticleId><ArticleId IdType="pubmed">32398281</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Ruiz R, Paredes JL, Niewold TB (2020) COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res S1931-5244(20):30302–30309. https://doi.org/10.1016/j.trsl.2020.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.12.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez GA, Gerosa M, Beretta L, Bellocchi C, Argolini LM, Moroni L et al (2020) COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients. Semin Arthritis Rheum 50:1150–1157. https://doi.org/10.1016/j.semarthrit.2020.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.06.012</ArticleId><ArticleId IdType="pubmed">32927376</ArticleId><ArticleId IdType="pmcid">7836639</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Yao B, Yan M, Su K, Wang H, Xu C (2020) The plight of patients with lupus nephritis in Wuhan, China. J Rheumatol 47:1452. https://doi.org/10.3899/jrheum.200452</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200452</ArticleId><ArticleId IdType="pubmed">32385088</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B et al (2020) Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 79:837–839. https://doi.org/10.1136/annrheumdis-2020-217566</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217566</ArticleId><ArticleId IdType="pubmed">32332072</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R et al (2020) Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus. Arthritis Rheumatol 72:1971–1980. https://doi.org/10.1002/art.41450</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41450</ArticleId><ArticleId IdType="pubmed">32715660</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Espinosa, Gerard" sort="Espinosa, Gerard" uniqKey="Espinosa G" first="Gerard" last="Espinosa">Gerard Espinosa</name></region><name sortKey="Cervera, Ricard" sort="Cervera, Ricard" uniqKey="Cervera R" first="Ricard" last="Cervera">Ricard Cervera</name><name sortKey="Llevadot, Mireia" sort="Llevadot, Mireia" uniqKey="Llevadot M" first="Mireia" last="Llevadot">Mireia Llevadot</name><name sortKey="Marco Hernandez, Javier" sort="Marco Hernandez, Javier" uniqKey="Marco Hernandez J" first="Javier" last="Marco-Hernández">Javier Marco-Hernández</name><name sortKey="Martinez Artu A, Antonio" sort="Martinez Artu A, Antonio" uniqKey="Martinez Artu A A" first="Antonio" last="Martínez-Artu A">Antonio Martínez-Artu A</name><name sortKey="Perez Isidro, Albert" sort="Perez Isidro, Albert" uniqKey="Perez Isidro A" first="Albert" last="Pérez-Isidro">Albert Pérez-Isidro</name><name sortKey="Prieto Gonzalez, Sergio" sort="Prieto Gonzalez, Sergio" uniqKey="Prieto Gonzalez S" first="Sergio" last="Prieto-González">Sergio Prieto-González</name><name sortKey="Rife, Elia" sort="Rife, Elia" uniqKey="Rife E" first="Elia" last="Rifé">Elia Rifé</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000086 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000086 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33677725
|texte= The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33677725" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |